Real-world burden of primary hyperoxaluria with chronic kidney disease in the United States: a retrospective administrative claims analysis
CKD stage progression among patients who had PH is associated with increasing all-cause costs, suggesting that early diagnosis and treatment of PH to limit the progression to advanced CKD could represent an opportunity to alleviate not only PH symptoms, but also the healthcare cost burden.
Authors
- Frank Modersitzki (ORCID: https://orcid.org/0000-0002-5461-8637)
- Sandra Salem (ORCID: https://orcid.org/0009-0005-6732-0492)
- Olivia Li
- Jing Voon Chen (ORCID: https://orcid.org/0000-0003-3632-6806)
- David S. Goldfarb (ORCID: https://orcid.org/0000-0002-9215-1273)
- Jeffrey R. Skaar
Institutions
- Trinity Health (US)
- NYU Langone Health (US)
- Novo Nordisk (United States) (US)
- New York University (US)
Publication Details
- Journal
- BMC Nephrology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1186/s12882-025-04460-1
- Citations
- 1
- Primary Topic
- Kidney Stones and Urolithiasis Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- Novo Nordisk